• Flexibility in baseline profiling – tissue or liquid biopsy
• Ultra-sensitive MRD detection – 5 PPM
• Tracking up to 250 personalized mutations, including fusions
• Detecting 500 actionable mutations
• Including genome-wide copy number changes
Blood
Urine
Tissue
2-5 mL plasma
4-10 mL blood*
20-40 mL of urine
6 days
*CLIA-validated assay requires two tubes of 10mL blood. A minimum of 30ng cfDNA is recommended.
**Features for PredicineBEACON MRD detection. For baseline requirements, please consult.
PredicineBEACON™ is designed for ultra-sensitive MRD detection to address the following clinical questions beyond the capacity of conventional MRD assays:
MRD detection with PredicineBEACON™ is different from conventional MRD assays because it is not limited by baseline sample availability. If available, baseline samples can be assessed using patient’s blood, urine or tissue. If a baseline sample is unavailable, monitoring the recurrence or progression of cancer can be achieved with a simple blood draw or urine sample with our tissue-agnostic approach.
We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.
If you have any questions or need assistance, complete this form and we will respond within 24 hours.